MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is D3 Bio's Elisrasib a Game-Changer in KRAS G12C NSCLC

6 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did D3 Bio Present at ASCO 2026 for Elisrasib

2 hours ago

Is PetroChem Innovate's New Bio-Plastic a Game Changer for the Industry

1 months ago

What Makes Elisrasib's ASCO 2026 Data So Significant

2 hours ago

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

3 weeks ago

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

D3 Bio reported first-line clinical data for its next-generation KRAS G12C inhibitor, elisrasib (D3S-001), at the ASCO 2026 conference. The study highlights landmark efficacy results for the drug in p...

Stock News•1 week ago

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 has emerged as a primary target in oncology research, with a new natural killer (NK) cell engager entering clinical trials. This development marks a shift in cancer drug development toward this ...

GTBP

Stock News•1 months ago

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Elicio Therapeutics faces a critical 2026 as it approaches a pivotal KRAS peptide vaccine trial readout. While the data could serve as a significant catalyst for the company, ongoing concerns regardin...

ELTX

Stock News•1 months ago

Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.

Erasca shares fell 50% following the company's update on its cancer drug development program. The sell-off reflects investor concerns regarding the firm's competitive position against Revolution Medic...

ERAS